Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$8.63 - $15.52 $10,278 - $18,484
-1,191 Reduced 3.61%
31,758 $281,000
Q2 2022

Aug 12, 2022

BUY
$8.59 - $20.77 $146,030 - $353,090
17,000 Added 106.59%
32,949 $416,000
Q1 2022

May 13, 2022

BUY
$15.52 - $35.65 $14,914 - $34,259
961 Added 6.41%
15,949 $302,000
Q4 2021

Feb 14, 2022

BUY
$28.89 - $35.33 $8,667 - $10,599
300 Added 2.04%
14,988 $526,000
Q3 2021

Nov 12, 2021

BUY
$35.66 - $42.94 $42,791 - $51,528
1,200 Added 8.9%
14,688 $538,000
Q2 2021

Aug 13, 2021

BUY
$23.7 - $39.27 $33,180 - $54,978
1,400 Added 11.58%
13,488 $530,000
Q1 2021

May 14, 2021

BUY
$27.01 - $36.8 $13,883 - $18,915
514 Added 4.44%
12,088 $341,000
Q4 2020

Feb 12, 2021

SELL
$27.51 - $34.36 $34,002 - $42,468
-1,236 Reduced 9.65%
11,574 $371,000
Q3 2020

Nov 13, 2020

SELL
$25.8 - $34.61 $265,069 - $355,583
-10,274 Reduced 44.51%
12,810 $414,000
Q2 2020

Aug 14, 2020

SELL
$17.65 - $28.05 $51,184 - $81,345
-2,900 Reduced 11.16%
23,084 $637,000
Q1 2020

May 14, 2020

BUY
$15.19 - $29.51 $200,902 - $390,299
13,226 Added 103.67%
25,984 $464,000
Q4 2019

Feb 14, 2020

SELL
$17.17 - $25.95 $321,079 - $485,265
-18,700 Reduced 59.44%
12,758 $320,000
Q3 2019

Nov 14, 2019

SELL
$17.84 - $22.69 $360,029 - $457,906
-20,181 Reduced 39.08%
31,458 $561,000
Q2 2019

Aug 09, 2019

BUY
$22.0 - $31.78 $132,000 - $190,680
6,000 Added 13.15%
51,639 $1.14 Million
Q1 2019

May 14, 2019

SELL
$21.27 - $30.58 $1.01 Million - $1.45 Million
-47,261 Reduced 50.87%
45,639 $1.4 Million
Q4 2018

Feb 14, 2019

BUY
$23.09 - $37.69 $2.15 Million - $3.5 Million
92,900 New
92,900 $2.15 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Caisse De Depot Et Placement Du Quebec Portfolio

Follow Caisse De Depot Et Placement Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caisse De Depot Et Placement Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Caisse De Depot Et Placement Du Quebec with notifications on news.